S&P 500   4,679.49 (+1.91%)
DOW   35,718.58 (+1.40%)
QQQ   395.28 (+2.35%)
AAPL   169.96 (+2.81%)
MSFT   332.66 (+1.98%)
FB   323.09 (+1.64%)
GOOGL   2,922.35 (+2.07%)
AMZN   3,497.70 (+2.05%)
TSLA   1,045.15 (+3.58%)
NVDA   308.92 (+2.85%)
BABA   126.46 (+2.31%)
NIO   32.96 (+1.92%)
CGC   10.45 (+2.96%)
AMD   141.62 (+1.84%)
GE   97.46 (+1.51%)
MU   85.77 (+4.03%)
T   23.32 (+0.17%)
F   19.63 (+2.13%)
DIS   152.23 (+1.24%)
PFE   51.59 (+0.21%)
AMC   30.12 (+4.62%)
ACB   6.17 (+3.35%)
BA   209.18 (+1.60%)
S&P 500   4,679.49 (+1.91%)
DOW   35,718.58 (+1.40%)
QQQ   395.28 (+2.35%)
AAPL   169.96 (+2.81%)
MSFT   332.66 (+1.98%)
FB   323.09 (+1.64%)
GOOGL   2,922.35 (+2.07%)
AMZN   3,497.70 (+2.05%)
TSLA   1,045.15 (+3.58%)
NVDA   308.92 (+2.85%)
BABA   126.46 (+2.31%)
NIO   32.96 (+1.92%)
CGC   10.45 (+2.96%)
AMD   141.62 (+1.84%)
GE   97.46 (+1.51%)
MU   85.77 (+4.03%)
T   23.32 (+0.17%)
F   19.63 (+2.13%)
DIS   152.23 (+1.24%)
PFE   51.59 (+0.21%)
AMC   30.12 (+4.62%)
ACB   6.17 (+3.35%)
BA   209.18 (+1.60%)
S&P 500   4,679.49 (+1.91%)
DOW   35,718.58 (+1.40%)
QQQ   395.28 (+2.35%)
AAPL   169.96 (+2.81%)
MSFT   332.66 (+1.98%)
FB   323.09 (+1.64%)
GOOGL   2,922.35 (+2.07%)
AMZN   3,497.70 (+2.05%)
TSLA   1,045.15 (+3.58%)
NVDA   308.92 (+2.85%)
BABA   126.46 (+2.31%)
NIO   32.96 (+1.92%)
CGC   10.45 (+2.96%)
AMD   141.62 (+1.84%)
GE   97.46 (+1.51%)
MU   85.77 (+4.03%)
T   23.32 (+0.17%)
F   19.63 (+2.13%)
DIS   152.23 (+1.24%)
PFE   51.59 (+0.21%)
AMC   30.12 (+4.62%)
ACB   6.17 (+3.35%)
BA   209.18 (+1.60%)
S&P 500   4,679.49 (+1.91%)
DOW   35,718.58 (+1.40%)
QQQ   395.28 (+2.35%)
AAPL   169.96 (+2.81%)
MSFT   332.66 (+1.98%)
FB   323.09 (+1.64%)
GOOGL   2,922.35 (+2.07%)
AMZN   3,497.70 (+2.05%)
TSLA   1,045.15 (+3.58%)
NVDA   308.92 (+2.85%)
BABA   126.46 (+2.31%)
NIO   32.96 (+1.92%)
CGC   10.45 (+2.96%)
AMD   141.62 (+1.84%)
GE   97.46 (+1.51%)
MU   85.77 (+4.03%)
T   23.32 (+0.17%)
F   19.63 (+2.13%)
DIS   152.23 (+1.24%)
PFE   51.59 (+0.21%)
AMC   30.12 (+4.62%)
ACB   6.17 (+3.35%)
BA   209.18 (+1.60%)
NASDAQ:ADVM

Adverum Biotechnologies Stock Forecast, Price & News

$1.81
+0.04 (+2.26%)
(As of 12/7/2021 09:56 AM ET)
Add
Compare
Today's Range
$1.81
$1.84
50-Day Range
$1.74
$2.40
52-Week Range
$1.69
$14.79
Volume
3,817 shs
Average Volume
1.98 million shs
Market Capitalization
$177.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.16
30 days | 90 days | 365 days | Advanced Chart
Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.


Adverum Biotechnologies logo

About Adverum Biotechnologies

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Headlines

Adverum Biotechnologies, Inc.(ADVM)
November 12, 2021 |  fool.com
Adverum Reports Third Quarter 2021 Results
November 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADVM
Employees
167
Year Founded
N/A

Sales & Book Value

Annual Sales
$250 thousand
Book Value
$3.53 per share

Profitability

Net Income
$-117.51 million
Pretax Margin
-1,968.65%

Debt

Price-To-Earnings

Miscellaneous

Free Float
94,030,000
Market Cap
$177.66 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/07/2022

MarketRank

Overall MarketRank

2.18 out of 5 stars

Medical Sector

423rd out of 1,394 stocks

Biological Products, Except Diagnostic Industry

67th out of 202 stocks

Analyst Opinion: 3.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -












Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

Is Adverum Biotechnologies a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last twelve months. There are currently 9 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Adverum Biotechnologies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADVM, but not buy additional shares or sell existing shares.
View analyst ratings for Adverum Biotechnologies
or view top-rated stocks.

How has Adverum Biotechnologies' stock been impacted by COVID-19?

Adverum Biotechnologies' stock was trading at $9.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ADVM shares have decreased by 80.5% and is now trading at $1.81.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Adverum Biotechnologies?

Adverum Biotechnologies saw a drop in short interest in November. As of November 15th, there was short interest totaling 6,960,000 shares, a drop of 19.7% from the October 31st total of 8,670,000 shares. Based on an average daily volume of 2,040,000 shares, the days-to-cover ratio is presently 3.4 days. Currently, 9.2% of the shares of the company are short sold.
View Adverum Biotechnologies' Short Interest
.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Adverum Biotechnologies
.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) released its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.01.
View Adverum Biotechnologies' earnings history
.

What price target have analysts set for ADVM?

9 brokerages have issued twelve-month price objectives for Adverum Biotechnologies' stock. Their forecasts range from $2.00 to $13.00. On average, they anticipate Adverum Biotechnologies' stock price to reach $6.43 in the next year. This suggests a possible upside of 255.2% from the stock's current price.
View analysts' price targets for Adverum Biotechnologies
or view top-rated stocks among Wall Street analysts.

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the following people:
  • Laurent Fischer, President, CEO, Director & Chief Medical Officer (LinkedIn Profile)
  • Peter Soparkar, Chief Operating Officer
  • Jack Anthony Thrift, Chief Financial & Accounting Officer
  • Brigit Riley, Chief Scientific Officer
  • Jon Williams, Vice President-Clinical Affairs

What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?

3 employees have rated Adverum Biotechnologies CEO Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among Adverum Biotechnologies' employees.

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RTW Investments LP (7.62%), BlackRock Inc. (7.58%), UBS Group AG (3.20%), Two Sigma Investments LP (1.91%), Two Sigma Advisers LP (1.80%) and K2 Principal Fund L.P. (1.69%). Company insiders that own Adverum Biotechnologies stock include James Paul Scopa, Julie Clark, Laurent Fischer, Leone D Patterson, Mehdi Gasmi, Patrick Machado and Peter Soparkar.
View institutional ownership trends for Adverum Biotechnologies
.

Which institutional investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., BlackRock Inc., Dimensional Fund Advisors LP, Deutsche Bank AG, Rafferty Asset Management LLC, Citadel Advisors LLC, Assenagon Asset Management S.A., and WS Management Lllp. Company insiders that have sold Adverum Biotechnologies company stock in the last year include James Paul Scopa, Julie Clark, and Leone D Patterson.
View insider buying and selling activity for Adverum Biotechnologies
or view top insider-selling stocks.

Which institutional investors are buying Adverum Biotechnologies stock?

ADVM stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Millennium Management LLC, K2 Principal Fund L.P., Morgan Stanley, Connor Clark & Lunn Investment Management Ltd., Two Sigma Investments LP, Renaissance Technologies LLC, and 683 Capital Management LLC. Company insiders that have bought Adverum Biotechnologies stock in the last two years include James Paul Scopa, Laurent Fischer, Patrick Machado, and Peter Soparkar.
View insider buying and selling activity for Adverum Biotechnologies
or or view top insider-buying stocks.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $1.81.

How much money does Adverum Biotechnologies make?

Adverum Biotechnologies has a market capitalization of $177.66 million and generates $250 thousand in revenue each year. The biotechnology company earns $-117.51 million in net income (profit) each year or ($1.52) on an earnings per share basis.

How many employees does Adverum Biotechnologies have?

Adverum Biotechnologies employs 167 workers across the globe.

What is Adverum Biotechnologies' official website?

The official website for Adverum Biotechnologies is www.adverum.com.

Where are Adverum Biotechnologies' headquarters?

Adverum Biotechnologies is headquartered at 800 Saginaw Drive, Redwood City CA, 94063.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company can be reached via phone at (650) 656-9323, via email at [email protected], or via fax at 650-329-8151.


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.